Tuesday, April 24th, ALXN announced financial
results for the three months ended March 31, 2012. ALXN continues to beat
Street expectations, beating revenue estimates by roughly $3 million and $0.08
in earnings. ALXN reported net sales from their revolutionary drug, Soliris, of
$244.7 million, representing a 47% increase year-over-year. Revenue performance
is a reflection of added PNH patients in the U.S., Western Europe, Japan and in
other countries, augmented by a steady increase in new patients from the aHUS
indication. GAAP net income also increased 69% to $45.4 million or simply $0.23
per share, compared to $26.8 million and $0.29 year-over-year. Furthermore,
ALXN recognized $359 million in cash compared to $541 million at year end 2011.
This change reflects positive cash flow from operations during the quarter and
acquisition-related debt, offset by the outflows from the Enobia purchase. In
addition, GAAP operating expenses increased to $146.4 million, compared to
$106.7 million year-over-year, primarily due to an increase in R&D,
SG&A, and acquisition-related expenses. Management also gave optimistic forecasting
by increasing and narrowing 2012 revenue guidance, previously in the range of
$1.04-1.07 billion to $1.065-1.085 billion. With this increased forecast,
combined with the control of expenses within previously guided ranges, ALXN is
also raising non-GAAP earnings from the range of $1.60-1.70 to a higher range
of $1.65-1.75. However, despite positive
earnings, the stock dipped due to the lack of expected quantitative results and
forecasts on the developing pipeline. That being said, ALXN’s annual shareholder
meeting is set for May, 7th, where additional insight is anticipated
to be visible.
-Shawn Laljit